Handelsbanken Fonder’s Crinetics Pharmaceuticals CRNX Stock Holding History

Handelsbanken Fonder’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	36,000 +6,500	+22%	+$242K	﹤0.01%	996
2026 Q1	$1.07M	Hold	29,500	–	–	﹤0.01%	1002
2025 Q4	$1.37M	Sell	29,500 -2,600	-8%	-$116K	﹤0.01%	902
2025 Q3	$1.34M	Buy	32,100 +7,600	+31%	+$243K	﹤0.01%	889
2025 Q2	$705K	Buy	24,500 +2,700	+12%	+$83.4K	﹤0.01%	1104
2025 Q1	$731K	Hold	21,800	–	–	﹤0.01%	1074
2024 Q4	$1.11M	Buy	21,800 +2,800	+15%	+$157K	﹤0.01%	922
2024 Q3	$971K	Buy	19,000 +2,600	+16%	+$134K	﹤0.01%	956
2024 Q2	$735K	Buy	16,400 +3,100	+23%	+$143K	﹤0.01%	982
2024 Q1	$623K	Buy	13,300 +800	+6%	+$31.3K	﹤0.01%	1064
2023 Q4	$445K	Buy	+12,500	New	+$383K	﹤0.01%	1205

Other funds holding CRNX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

LAM

Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Handelsbanken Fonder's CRNX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Crinetics Pharmaceuticals (CRNX) stake by 22% in Q2 2026, buying an estimated $242K and bringing the position to 36,000 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Handelsbanken Fonder first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.37M in Q4 2025. 52 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Handelsbanken Fonder held 36,000 shares of Crinetics Pharmaceuticals worth $1.35M as of Q2 2026.
Handelsbanken Fonder bought 6,500 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $242K.
Crinetics Pharmaceuticals made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #996 holding.
Handelsbanken Fonder first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Handelsbanken Fonder's Crinetics Pharmaceuticals position peaked at $1.37M in Q4 2025.
52 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.